JAM3

Across TCGA pan-cancer cohorts, JAM3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated JAM3 data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher JAM3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated JAM3 expression acts as an unfavorable survival marker.

UCS, UCEC, and LIHC are the cancer types where JAM3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.001	0.690	<.001	36	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.113	0.544	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

JAM3–UCS (OS)

Open the UCS breakdown →